Immunic, Inc.
IMUX
$0.65
$0.00-0.31%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.00M | 19.38M | 18.15M | 18.01M | 18.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.53M | 105.27M | 101.00M | 98.05M | 95.80M |
| Operating Income | -105.53M | -105.27M | -101.00M | -98.05M | -95.80M |
| Income Before Tax | -103.05M | -101.84M | -96.40M | -100.51M | -96.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -103.05 | -101.84 | -96.40 | -100.51 | -96.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.05M | -101.84M | -96.40M | -100.51M | -96.90M |
| EBIT | -105.53M | -105.27M | -101.00M | -98.05M | -95.80M |
| EBITDA | -105.37M | -105.10M | -100.85M | -97.92M | -95.68M |
| EPS Basic | -0.94 | -1.05 | -0.98 | -1.01 | -1.24 |
| Normalized Basic EPS | -0.57 | -0.64 | -0.60 | -0.60 | -0.74 |
| EPS Diluted | -0.94 | -1.05 | -0.98 | -1.01 | -1.24 |
| Normalized Diluted EPS | -0.57 | -0.64 | -0.60 | -0.60 | -0.74 |
| Average Basic Shares Outstanding | 483.40M | 390.78M | 393.40M | 400.55M | 344.44M |
| Average Diluted Shares Outstanding | 483.40M | 390.78M | 393.40M | 400.55M | 344.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |